SCHEMBL15420590

SCHEMBL15420590

CCS(=O)(=O)N[C@H]1CCCO[C@@H]1COc1ccc(-c2coc(C)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TP53 P04637 9/20 0.46
THRB P10828 3/20 0.46
POLB P06746 3/20 0.46
TDP1 Q9NUW8 1/20 0.46
MAPT P10636 1/20 0.42
ENPP3 O14638 2/20 0.41
ENPP1 P22413 1/20 0.41
LMNA P02545 2/20 0.40
MAPK1 P28482 1/20 0.40
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15420746 0.91 TP53 (0.44) TP53THRBPOLBTDP1MAPT
SCHEMBL15420297 0.90 TP53 (0.43) TP53THRBPOLBTDP1MAPT
SCHEMBL15420505 0.85 LMNA (0.52) POLBLMNAMAPK1MEN1NPC1
SCHEMBL15419836 0.83 LMNA (0.38) POLBTDP1MAPTLMNAMAPK1
SCHEMBL15420213 0.81 LMNA (0.38) POLBTDP1LMNAMAPK1NPC1
SCHEMBL15441636 0.81 TP53 (0.46) TP53THRBPOLBTDP1MAPT
SCHEMBL15420407 0.81 GRIA2 (0.41) POLBMAPTLMNAMAPK1NPC1
SCHEMBL15420013 0.81 TP53 (0.46) TP53THRBPOLBTDP1MAPT
SCHEMBL15420721 0.81 TP53 (0.46) TP53THRBPOLBTDP1MAPT
SCHEMBL15420096 0.80 KDM4E (0.45) POLBMAPTLMNAMAPK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694472-B1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2020-03-11 EP disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF GRIN2A, GRIN2B, SLC1A2 TP53 2416/4885THRB 686/4885POLB 3654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.